Rakovina Therapeutics’ private placement fuels DNA-damage response therapies

Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company pioneering innovative cancer therapies through advancements in DNA-damage response technologies, has successfully closed an oversubscribed private placement ... Read More